What's Happening With These Generic Drugs Stocks? -- Medicines, Mylan, Neurocrine Biosciences, and Rigel Pharma

Tuesday, January 23, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 23, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment

community.  Today we are offering reports on MDCO, MYL, NBIX, and RIGL which can be accessed for free by signing up to www.wallstequities.com/registration. Research coverage has been initiated by WallStEquities.com on The Medicines Co. (NASDAQ: MDCO),
Mylan N.V. (NASDAQ: MYL), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Companies in the Generic Pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse. All you have to do is sign up today for this free limited time offer by clicking the link below.


The Medicines Co.

On Monday, shares in New Jersey-based The Medicines Co. jumped 16.03%, ending the day at $28.81. The stock recorded a trading volume of 4.00 million shares, which was above its three months average volume of 1.23 million shares. The Company's shares have advanced 9.88% in the last month. The stock is trading above its 50-day moving average by 2.02%. Moreover, shares of Medicines have a Relative Strength Index (RSI) of 57.08.  

On January 08th, 2018, The Medicines Co. announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. (MLNT) for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of MLNT common stock; tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv®, and Minocin® IV; and the assumption by MLNT of all royalty, milestone, and other payment obligations relating to those products. Get the full research report on MDCO for free by clicking below at: www.wallstequities.com/registration/?symbol=MDCO


Shares in UK-based Mylan N.V. ended the day 1.95% higher at $47.64 with a total trading volume of 4.72 million shares. In the last month and the previous three months, the stock has gained 15.52% and 24.42%, respectively. Additionally, the Company's shares have advanced 28.51% over the past year. The stock is trading above its 50-day and 200-day moving averages by 17.71% and 27.46%, respectively. Furthermore, shares of Mylan have an RSI of 82.56. 

On January 04th, 2018, research firm Citigroup reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $48 a share to $58 a share.

On January 08th, 2018, Mylan announced that it is completing its previously-approved $1 billion share repurchase plan. The Company's Chairman Robert J. Coury commented: "This return of capital to our shareholders comes at a time of positive momentum for Mylan, with the recent launches and approvals of several key products, our strong future growth expectations, and our belief that the diversified and unique platform we have built is substantially undervalued." Today's complimentary research report on MYL is accessible at: www.wallstequities.com/registration/?symbol=MYL

Neurocrine Biosciences

On Monday, shares in California headquartered Neurocrine Biosciences Inc. finished 5.59% higher at $85.19. A total volume of 1.15 million shares was traded, which was above their three months average volume of 1.01 million shares. The stock has surged 23.68% in the last month, 44.49% over the previous three months, and 106.42% over the past year. The Company's shares are trading above their 50-day moving average by 14.97%. Additionally, Neurocrine Biosciences' stock has an RSI of 64.92. 

On January 07th, 2018, Neurocrine Biosciences announced that Christopher O'Brien, M.D., Chief Medical Officer, has notified the Company of his plans to retire in February 2018, after a transition period with his successor, Eiry W. Roberts, M.D. Dr. O'Brien joined the Company in 2005, and has led its clinical development and medical affairs activities for more than 12 years. He will remain as an exclusive consultant for the Company. Register now for your free research document on NBIX at: www.wallstequities.com/registration/?symbol=NBIX

Rigel Pharmaceuticals

California-based Rigel Pharmaceuticals Inc.'s shares recorded a trading volume of 2.15 million shares at the end of yesterday's session, which was above their three months average volume of 1.35 million shares. The stock closed the day 7.33% higher at $4.54. The Company's shares have advanced 35.52% in the past month and 106.36% over the past year. The stock is trading above its 50-day and 200-day moving averages by 17.39% and 48.43%, respectively. Additionally, shares of Rigel Pharma have an RSI of 69.67.  

On January 05th, 2018, Rigel Pharma announced that on December 23rd, 2017 and January 02nd, 2018, the Compensation Committee of its Board of Directors approved the grants of inducement stock options to purchase an aggregate of 200,000 shares of common stock to 12 new employees. These awards were granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4). Click on the link below and see our free report on RIGL at: www.wallstequities.com/registration/?symbol=RIGL


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-generic-drugs-stocks----medicines-mylan-neurocrine-biosciences-and-rigel-pharma-300586550.html

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store